Skip to main content
SpringerLink
Log in

Investigating investment in biopharmaceutical R&D

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Characteristics of US-located biopharmaceutical companies with US initial public offerings between 2010 and 2014.
Figure 2: Comparison of the value of small-molecule and biologics projects.

Acknowledgements

E.R.B.'s research was supported in part by a National Institutes of Health (NIH) grant NIANIH/R01AG043560 to the National Bureau of Economic Research (NBER). Views expressed in this article are those of the authors, and are not necessarily those of the NIH or the NBER.

Author information

Authors and Affiliations

  1. Bristol-Myers Squibb Company, Research & Development, Route 206 and Province Line Road, Princeton, 08543, New Jersey, USA

    Percy H. Carter

  2. Sloan School of Management, Massachusetts Institute of Technology, 100 Main Street, Cambridge, 02139, Massachusetts, USA

    Ernst R. Berndt & Mark Trusheim

  3. Tufts Center for the Study of Drug Development, Tufts University, 75 Kneeland Street, Boston, 02111, Massachusetts, USA

    Joseph A. DiMasi

Authors
  1. Percy H. Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernst R. Berndt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph A. DiMasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark Trusheim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Percy H. Carter.

Ethics declarations

Competing interests

P.H.C is an employee and shareholder of Bristol-Myers Squibb. M.T. is President of Co-Bio Consulting L.L.C., which provides management consulting services to biomedical firms.

Supplementary information

Supplementary information S1 (box)

Data sources and categorization for biopharmaceutical company IPOs: 2010–2014 (PDF 377 kb)

Supplementary information S2 (box)

Investment model (PDF 531 kb)

Supplementary information

Supplementary information S3 (table) (XLSX 101 kb)

Supplementary information S4 (box)

Discussion of factors that potentially underpin the paradoxical findings (PDF 220 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carter, P., Berndt, E., DiMasi, J. et al. Investigating investment in biopharmaceutical R&D. Nat Rev Drug Discov 15, 673–674 (2016). https://doi.org/10.1038/nrd.2016.104

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.104

  • Springer Nature Limited

This article is cited by

Search

Navigation